FDA Drops “Suicidality” Term, Urges Broader Risk Assessment During Development
Executive Summary
Revised draft guidance retains eight categories of drugs to be evaluated for suicidal ideation and behavior in clinical trials, but says assessments could be conducted more broadly and “encourages” sponsors to discuss the possibility with the review division.